Thomas J Hwang
Biographic Data
| ID | 8449648 |
|---|---|
| NAME | Thomas J Hwang |
| GIVEN NAMES | Thomas J |
| FAMILY NAME | Hwang |
| SIGNATURE | HWANG T J |
| AFFILIATIONS | Brigham and Women's Hospital |
| ORCID | 0000-0003-0717-1497 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
New Medicare Payment Policy on Drug Shortages
This Viewpoint describes the Centers for Medicare & Medicaid Services’ new payment policy to establish and maintain buffer supplies of designated essential medicines and suggests additional reforms to improve this policy
Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
In this cross-sectional study of 18 top-selling brand-name drugs, excluding 1 anomaly, Medicaid average net prices declined from 2015 to 2019. Simultaneously, for non-Medicaid payers, net price increased more than previously published marketwide growth rates, raising the importance of restraining drug price growth in non-Medicaid markets. Rigorous and transparent methods to estimate Medicaid discounts are imperative to understand patterns in Medi…
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
Transparency in Health and Health Care in the United States
No prominent works on this page.
Transparency in Health and Health Care in the United States
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
In this cross-sectional study of 18 top-selling brand-name drugs, excluding 1 anomaly, Medicaid average net prices declined from 2015 to 2019. Simultaneously, for non-Medicaid payers, net price increased more than previously published marketwide growth rates, raising the importance of restraining drug price growth in non-Medicaid markets. Rigorous and transparent methods to estimate Medicaid discounts are imperative to understand patterns in Medi…
New Medicare Payment Policy on Drug Shortages
This Viewpoint describes the Centers for Medicare & Medicaid Services’ new payment policy to establish and maintain buffer supplies of designated essential medicines and suggests additional reforms to improve this policy
Health Systems, Economic Evaluations, Quality of Life (3 works) · Pharmaceutical Economics and Policy (3 works) · Pharmaceutical industry and healthcare (3 works) · Business (2 works) · Drug (2 works) · Medicaid (2 works) · Medicine (2 works) · Pharmacology (2 works) · Actuarial science (1 work) · Agency (philosophy (1 work)